Celldex Therapeutics, Inc. $CLDX Shares Sold by Simplify Asset Management Inc.

Simplify Asset Management Inc. reduced its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 59.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,629 shares of the biopharmaceutical company’s stock after selling 31,505 shares during the quarter. Simplify Asset Management Inc.’s holdings in Celldex Therapeutics were worth $701,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of CLDX. Nykredit A S bought a new stake in Celldex Therapeutics in the 2nd quarter valued at $67,000. Sterling Capital Management LLC grew its position in Celldex Therapeutics by 355.2% in the 3rd quarter. Sterling Capital Management LLC now owns 2,376 shares of the biopharmaceutical company’s stock worth $77,000 after purchasing an additional 1,854 shares during the last quarter. Abel Hall LLC increased its holdings in shares of Celldex Therapeutics by 6.8% during the 3rd quarter. Abel Hall LLC now owns 6,237 shares of the biopharmaceutical company’s stock worth $202,000 after purchasing an additional 399 shares during the period. Walleye Capital LLC bought a new position in shares of Celldex Therapeutics during the 1st quarter worth about $258,000. Finally, Amundi bought a new position in shares of Celldex Therapeutics during the 1st quarter worth about $297,000.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Barclays upped their price objective on shares of Celldex Therapeutics from $48.00 to $53.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Cantor Fitzgerald lifted their target price on Celldex Therapeutics from $61.00 to $72.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 22nd. Canaccord Genuity Group lowered their price target on Celldex Therapeutics from $62.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, July 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Thursday, October 15th. Finally, Wall Street Zen upgraded Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, July 12th. Eleven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Celldex Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $63.08.

Celldex Therapeutics Stock Performance

Shares of Celldex Therapeutics stock opened at $29.66 on Thursday. The firm’s 50-day simple moving average is $34.49 and its 200-day simple moving average is $32.55. Celldex Therapeutics, Inc. has a twelve month low of $22.10 and a twelve month high of $45.14. The firm has a market cap of $2.33 billion, a P/E ratio of -6.82 and a beta of 0.90.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $0.12. The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.73 million. On average, equities analysts forecast that Celldex Therapeutics, Inc. will post -4.17 earnings per share for the current fiscal year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing targeted therapeutics for diseases with significant unmet medical needs. The company uses antibody-based technologies to develop treatments intended to modulate the immune system and address inflammatory, autoimmune and other serious conditions.

Celldex’s lead investigational product is barzolvolimab, an antibody designed to selectively block the KIT receptor and reduce mast-cell activity.